TABLE 1.
Patient characteristics
| Study center 1 | Study center 2 | Total | |
|---|---|---|---|
| Characteristicsa | (n = 60) | (n = 13) | (n = 73) |
| Sex | |||
| Male | 43 (72%) | 10 (77%) | 53 (73%) |
| Female | 17 (28%) | 3 (23%) | 20 (27%) |
| Age (yrs) | |||
| Median (range) | 56 (19–87) | 76 (55–89) | 60 (19–89) |
| Wt (kg) | |||
| Median (range) | 77 (48–140) | 85 (55–120) | 77 (48–140) |
| Ht (cm) | |||
| Median (range) | 170 (150–190) | 170 (160–190) | 170 (150–190) |
| Serum albumin (g/L) | |||
| Median (range) | 25 (17–39) | 18 (8.0–28) | 23 (8.0–39) |
| Serum creatinine (mg/dL) | |||
| Median (range) | 2.0 (0.60–6.1) | 2.3 (0.90–8.6) | 2.1 (0.60–8.6) |
| eGFR(Cockcroft-Gault) (mL/min) | |||
| Median (range) | 47 (18–180) | 36 (5.2–62) | 44 (5.2–180) |
| eGFR(CKD-Epi) (mL/min/1.73m²) | |||
| Median (range) | 36 (11–120) | 26 (5.2–84) | 32 (5.2–120) |
| Dialysis type | |||
| CVVH | 43 (72%) | 0 (0%) | 43 (59%) |
| CVVHD | 10 (17%) | 13 (100%) | 23 (32%) |
| CVVHDF | 7 (12%) | 0 (0%) | 7 (10%) |
| Total flow rate (mL/h) | |||
| Median (range) | 2,000 (1,500–5,700) | 2,000 (2,000–2,000) | 2,000 (1,500–5,700) |
| Residual diuresis (mL/24 h) | |||
| Median (range) | 0 (0–1,500) | 1,000 (0–1,000) | 0 (0–1,500) |
| Dosing strategy | |||
| N patients (II/CI) | 56/4 | 13 | 56/17 |
| Sampling strategy | |||
| No. samples (total) | 167 | 26 | 193 |
| No. patients (>2 samples) | 11 | 0 | 11 |
a
N, Number of patients; Total flow rate, sum of dialysate flow and replacement fluid flow; eGFR, estimated glomerular filtration rate; CKD-Epi, chronic kidney disease epidemiology collaboration; CVVH, continuous veno-venous filtration; CVVHD, continuous veno-venous hemodialysis; CVVHD, continuous veno-venous hemodiafiltration; II, intermittent infusion; CI, continuous infusion.